NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA
NCT02499952 2022-07-11Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell TumorsHoosier Cancer Research NetworkPhase 2 Terminated12 enrolled 14 charts
NCT02689219 2019-12-10Brentuximab Vedotin in Relapsed/Refractory Germ Cell TumorsIndiana UniversityPhase 2 Terminated18 enrolled 13 charts